Lodestone’s bio-compatible implant opens the door to a broad spectrum of longitudinal in vivo assays targeting cytokine levels and other molecules.
Our small-animal system and in vivo assay platform accelerates drug development and increases the success rate of your pre-clinical trials.
Each probe contains a few micro-gram of bio-compatible magnetic nanoparticles that are that are functionalized to bind to the targeted molecule. A semi-permeable membrane retains the nanoparticles but allows biomolecules to enter the probe.
Once the targeted molecules enter the probe the nanoparticles form clusters and aggregate. This changes their magnetic signal and can be read out with Lodestone's measurement systems.
Similar to ELISA the nanoparticle assay can be functionalized to target virtually any molecule.
Lodestone’s first in vivo measurement system allows scientists to accelerate pre-clinical drug development. With the SNS multiple probes can be measured per mouse in as little as 30 seconds per measurement. Collect longitudinal measurement data in your region of interest for up to seven days after implantation.
Lodestone’s NCS is a liquid cooled spectrometer which can characterize smallest amounts of magnetic nanoparticles in complex field patterns. The multi-coil spectrometer is capable of analyzing the magnetic particle response of Lodestone's probes in an in vitro setting in different media.
Lodestone is currently working on the next generation of its magnetic spectrometer that will be capable to support clinical trials. With the open design of the clinical prototype in vivo measurements with probes implanted up to 15 cm deep will be carried out. IRIS probes placed in the tumor microenvironment will work as treatment response indicator, measuring the activity of immune system through the detection of cytokine levels.